ALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs

Deep News

昨天

ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion.

HSBC Global Research noted that health products are expected to continue being ALI HEALTH's fastest-growing category, benefiting from its robust platform ecosystem. Regarding pharmaceuticals, while the company's continued focus on first-party sales (1P) profitability may limit sales growth, the firm believes that as social insurance claims tighten and offline traffic shifts online, ALI HEALTH will benefit from strong demand for innovative drugs. Combined with strong advertising momentum, HSBC has raised its revenue growth forecast for ALI HEALTH's fiscal year 2026 from the previous 9% year-over-year to 15% year-over-year. Profit margins are expected to improve due to the revenue structure shifting toward non-pharmaceutical products and enhanced 1P profit margins, with the company's fiscal year 2026 net profit growth potentially exceeding revenue growth.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1126765801"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126765801\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126765801?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 12:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126765801","market":"sh","top_or_hot":-1,"title":"ALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs","media":"Deep News","content":"<p>ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion.</p>\n<p>HSBC Global Research noted that health products are expected to continue being ALI HEALTH's fastest-growing category, benefiting from its robust platform ecosystem. Regarding pharmaceuticals, while the company's continued focus on first-party sales (1P) profitability may limit sales growth, the firm believes that as social insurance claims tighten and offline traffic shifts online, ALI HEALTH will benefit from strong demand for innovative drugs. Combined with strong advertising momentum, HSBC has raised its revenue growth forecast for ALI HEALTH's fiscal year 2026 from the previous 9% year-over-year to 15% year-over-year. Profit margins are expected to improve due to the revenue structure shifting toward non-pharmaceutical products and enhanced 1P profit margins, with the company's fiscal year 2026 net profit growth potentially exceeding revenue growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-09-09 12:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion.</p>\n<p>HSBC Global Research noted that health products are expected to continue being ALI HEALTH's fastest-growing category, benefiting from its robust platform ecosystem. Regarding pharmaceuticals, while the company's continued focus on first-party sales (1P) profitability may limit sales growth, the firm believes that as social insurance claims tighten and offline traffic shifts online, ALI HEALTH will benefit from strong demand for innovative drugs. Combined with strong advertising momentum, HSBC has raised its revenue growth forecast for ALI HEALTH's fiscal year 2026 from the previous 9% year-over-year to 15% year-over-year. Profit margins are expected to improve due to the revenue structure shifting toward non-pharmaceutical products and enhanced 1P profit margins, with the company's fiscal year 2026 net profit growth potentially exceeding revenue growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1142","symbol_name":"互联网与直销零售","start_time":0,"source_url":"","article_id":"1126765801","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126765801","pubTimestamp":1757391650,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion. HSBC Global Research noted that health products are expected to continue being...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1142":"互联网与直销零售","BK1502":"双十一","BK1591":"就地过年概念","BK1615":"港股-互联网","BK1189":"医疗保健技术","BK1247":"药品零售","BK1584":"蚂蚁金服概念","BK1501":"阿里概念股","BK1571":"互联网医疗","BK1617":"AI医疗","00241":"阿里健康","BK1589":"北水核心资产","BK1515":"抗疫概念","BK1610":"ETF&股票定投概念"},"translate_title":"阿里健康早盘大涨超6%分析师预计公司将受益于创新药强劲需求","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00241":1},"content_text":"ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion.\nHSBC Global Research noted that health products are expected to continue being ALI HEALTH's fastest-growing category, benefiting from its robust platform ecosystem. Regarding pharmaceuticals, while the company's continued focus on first-party sales (1P) profitability may limit sales growth, the firm believes that as social insurance claims tighten and offline traffic shifts online, ALI HEALTH will benefit from strong demand for innovative drugs. Combined with strong advertising momentum, HSBC has raised its revenue growth forecast for ALI HEALTH's fiscal year 2026 from the previous 9% year-over-year to 15% year-over-year. Profit margins are expected to improve due to the revenue structure shifting toward non-pharmaceutical products and enhanced 1P profit margins, with the company's fiscal year 2026 net profit growth potentially exceeding revenue growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}